Compare ING Groep NV (ING) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Vaxcyte Inc. Common Stock — how do they compare? ING Groep NV trades at $33.34 (market cap $94.92B), while Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B). The key difference: ING Groep NV is far larger — about 9× Vaxcyte Inc. Common Stock's market cap, and ING Groep NV pays a 3.93% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 94 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| ING | PCVX | |
|---|---|---|
Market Cap | $94.92B | $10.51B |
Volume | 2,055,666 | 2,644,694 |
Sector | Financials | Health |
52-Week High | $37.27 | $73.82 |
52-Week Low | $23.66 | $40.32 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $237.77B | $9.14B |
Dividend Yield | 3.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $33.46, up 0.21% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.79 exceeding the $0.75 estimate. Revenue reached $22.90 billion in 2025, with a net income margin of 28.34%. Analyst sentiment is positive, with 11 buy ratings and no sell ratings among 17 analysts. Recent news highlights an upgraded ROE target above 16% for 2027 and strategic focus on organic growth.
The outlook for ING is cautiously optimistic, supported by earnings momentum and favorable analyst coverage. Key opportunities include revenue growth and profitability targets, while risks involve persistent negative operating cash flows and regulatory scrutiny, such as recent capital requirements in Australia. The stock's valuation metrics, including a P/E of 12.99, suggest reasonable pricing relative to earnings.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →
